** Shares of drugmaker Regeneron REGN.O fall 13.28% to $525 premarket
** Company and partner Sanofi SASY.PA say their experimental drug, itepekimab, failed in one late-stage trial testing it for a lung disease commonly called "smoker's lung", but met the goal of another trial
** Sanofi's U.S.-listed shares down ~6.5% before the bell
** Itepekimab was being tested in former smokers in two studies for chronic obstructive pulmonary disease, a condition that mostly affects smokers but can also be caused by pollutants
** Both trials were testing if the drug was statistically significant in reducing moderate or severe flare-ups of the condition in former smokers
** Companies are assessing the data and will discuss next steps with regulatory authorities
** REGN shares down ~15% YTD
(Reporting by Manas Mishra in Bengaluru)
((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。